111, Inc. Reports Q2 2025 Financial Results Amid Market Challenges

111 ( (YI) ) has shared an update.

On September 17, 2025, 111, Inc. announced its unaudited financial results for the second quarter of 2025, ending June 30. Despite a challenging macroeconomic environment, the company maintained operational profitability and positive operating cash flow for the first half of the year. Total operating expenses decreased by 9.3% year-over-year, and the company saw a 53.6% increase in sales revenue from marketing promotional products. The company’s strategic initiatives, including its ‘MANTIANXING’ supply chain project, have expanded fulfillment centers to 19 locations, significantly increasing inventory value and GMV. Although net revenues decreased by 6.4% compared to the same quarter last year, the company remains focused on leveraging technology to strengthen its market position and create sustainable value for shareholders.

The most recent analyst rating on (YI) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on 111 stock, see the YI Stock Forecast page.

Spark’s Take on YI Stock

According to Spark, TipRanks’ AI Analyst, YI is a Underperform.

The overall stock score reflects significant financial and technical challenges. The company’s negative equity and ongoing losses are major concerns, compounded by bearish technical indicators. The lack of profitability and absence of a dividend yield further weigh on the valuation.

To see Spark’s full report on YI stock, click here.

More about 111

111, Inc. is a tech-enabled healthcare platform company based in Shanghai, China. It focuses on reshaping the healthcare industry value chain by digitally empowering both upstream and downstream operations in the country.

Average Trading Volume: 14,391

Technical Sentiment Signal: Strong Sell

Current Market Cap: $51.17M

Learn more about YI stock on TipRanks’ Stock Analysis page.